AG
PCRX icon

Aperio Group’s Pacira BioSciences PCRX Stock Holding History

Aperio Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$681K Buy
11,374
+1,201
+12% +$70.3K ﹤0.01% 1808
2020
Q3 		$611K Sell
10,173
-241
-2% -$14K ﹤0.01% 1710
2020
Q2 		$547K Buy
10,414
+2,690
+35% +$112K ﹤0.01% 1730
2020
Q1 		$259K Sell
7,724
-2,143
-22% -$89K ﹤0.01% 1987
2019
Q4 		$447K Buy
+9,867
New +$419K ﹤0.01% 1864
2019
Q3 		– Sell
-4,298
Closed -$187K – 2634
2019
Q2 		$187K Buy
+4,298
New +$182K ﹤0.01% 2202

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Aperio Group's PCRX Position: Q4 2020 in Review

Aperio Group increased its Pacira BioSciences (PCRX) stake by 12% in Q4 2020, buying an estimated $70.3K and bringing the position to 11,374 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #1808.

Aperio Group first reported a position in PCRX in Q2 2019 and has held it in 6 quarters since. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2020.

  • Aperio Group held 11,374 shares of Pacira BioSciences worth $681K as of Q4 2020.
  • Aperio Group bought 1,201 Pacira BioSciences shares in Q4 2020, an estimated $70.3K.
  • Pacira BioSciences made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1808 holding.
  • Aperio Group first reported a position in Pacira BioSciences in Q2 2019 and has held it in 6 quarters since.
  • 260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.